- ¥33bn
- ¥60bn
- ¥46bn
- 55
- 83
- 89
- 90
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.13 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -16.85% | ||
| Dividend Yield (f) | 3.46% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.69 | ||
| Price to Tang. Book | 0.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.68 | ||
| EV to EBITDA | 6.17 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.44% | ||
| Return on Equity | 9.8% | ||
| Operating Margin | 12.08% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 33,793 | 33,990 | 35,426 | 40,889 | 46,138 | 50,800 | 53,929 | 4.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -30.35 | +31.27 | +28.99 | +11.66 | +53.98 | -36.64 | +6.72 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fuji Pharma Co., Ltd. is a Japan-based company mainly engaged in the manufacture and sale of medical products. The Company is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.
Directors
- Hirofumi Imai CHM (57)
- Takayuki Iwai PRE (55)
- Takayuki Kasai VPR
- Satoru Hiromi MDR (60)
- Seiichi Inoue MEO
- Toyoyuki Kamide MEO (54)
- Masayuki Osawa MEO
- Atsuya Mitsuhashi MEO (48)
- Yumiko Yamazaki MEO (58)
- Takanori Matsuo DSL
- Shuhei Morita DSL
- Takeshi Hirayama EXO (60)
- Hiroshi Kaihori EXO
- Yoshinari Kanayama EXO
- Masayuki Naganawa EXO
- Takahiro Nozaki EXO
- Kazuhisa Sakurai EXO
- Takeshi Sato EXO
- Yoshihiro Takada EXO
- Takanori Yoshisue EXO
- Naomi Aoyama IND
- Keiji Hirai IND (66)
- Tadahiro Kozawa IND (63)
- Minesaburo Miyake IND
- Shuichi Tanaka IND
- Masayuki Uchida IND (64)
- Robert Wesman IND
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 1st, 1965
- Public Since
- June 22nd, 1995
- No. of Shareholders
- 11,974
- No. of Employees
- 1,658
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 24,427,782
- Address
- 6F, CHIYODA-KU, 102-0075
- Web
- https://www.fujipharma.jp/
- Phone
- +81 335563344
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4554
Dividend For 4554.T - 3.0000 JPY
Dividend For 4554.T - 22.5000 JPY
Similar to 4554
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Fuji Pharma Co share price?
As of Today at 20:43 UTC, shares in Fuji Pharma Co are trading at ¥1,355. This share price information is delayed by 15 minutes.
How has the Fuji Pharma Co share price performed this year?
Shares in Fuji Pharma Co last closed at ¥1,355 and the price had moved by -12.18% over the past 365 days. In terms of relative price strength the Fuji Pharma Co share price has underperformed the Nikkei 225 Index by -7.46% over the past year.
What are the analyst and broker recommendations for Fuji Pharma Co?
The overall consensus recommendation for Fuji Pharma Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Fuji Pharma Co dividend yield?
The Fuji Pharma Co dividend yield is 3.14% based on the trailing twelve month period.
Does Fuji Pharma Co pay a dividend?
Last year, Fuji Pharma Co paid a total dividend of ¥43, and it currently has a trailing dividend yield of 3.14%.Looking ahead, shares in Fuji Pharma Co are due to go ex-dividend on 2025-09-29 and the next dividend pay date is 2025-06-01.
When does Fuji Pharma Co next pay dividends?
Fuji Pharma Co are due to go ex-dividend on 2025-09-29 and the next dividend pay date is 2025-06-01. The historic dividend yield on Fuji Pharma Co shares is currently 3.14%.
How do I buy Fuji Pharma Co shares?
To buy shares in Fuji Pharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fuji Pharma Co?
As of the previous close price of ¥1,355, shares in Fuji Pharma Co had a market capitalisation of ¥33bn.
Where are Fuji Pharma Co shares listed?
Here are the trading details for Fuji Pharma Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4554
What kind of share is Fuji Pharma Co?
Based on an overall assessment of its quality, value and momentum Fuji Pharma Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fuji Pharma Co share price forecast for 2025?
The analyst consensus target price for shares in Fuji Pharma Co is ¥2,275. That is 67.88% above the last closing price of ¥1,355.
Analysts covering Fuji Pharma Co currently have a consensus Earnings Per Share (EPS) forecast of ¥143 for the next financial year.
Find out moreWhat is the trend in the Fuji Pharma Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fuji Pharma Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +16.27%.
As of the last closing price of ¥1,355, shares in Fuji Pharma Co were trading -2.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fuji Pharma Co PE Ratio?
The Fuji Pharma Co PE ratio based on its reported earnings over the past 12 months is 9.13. The shares last closed at ¥1,355.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fuji Pharma Co?
Fuji Pharma Co's management team is headed by:
- Hirofumi Imai - CHM
- Takayuki Iwai - PRE
- Takayuki Kasai - VPR
- Satoru Hiromi - MDR
- Seiichi Inoue - MEO
- Toyoyuki Kamide - MEO
- Masayuki Osawa - MEO
- Atsuya Mitsuhashi - MEO
- Yumiko Yamazaki - MEO
- Takanori Matsuo - DSL
- Shuhei Morita - DSL
- Takeshi Hirayama - EXO
- Hiroshi Kaihori - EXO
- Yoshinari Kanayama - EXO
- Masayuki Naganawa - EXO
- Takahiro Nozaki - EXO
- Kazuhisa Sakurai - EXO
- Takeshi Sato - EXO
- Yoshihiro Takada - EXO
- Takanori Yoshisue - EXO
- Naomi Aoyama - IND
- Keiji Hirai - IND
- Tadahiro Kozawa - IND
- Minesaburo Miyake - IND
- Shuichi Tanaka - IND
- Masayuki Uchida - IND
- Robert Wesman - IND